
-
Synlogic Inc NASDAQ:SYBX Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic therapeutics that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX). The company is also building a portfolio of partner-able assets in immunology and oncology.
Location: 301 Binney St Ste 402, Massachusetts, 02142-1030, US | Website: www.synlogictx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-3.482M
Cash
19.39M
Avg Qtr Burn
-9.155M
Short % of Float
2.38%
Insider Ownership
14.19%
Institutional Own.
64.61%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SYNB1353 Details Homocystinuria | Phase 2 Initiation | |
SYNB8802 Details Primary hyperoxaluria | Phase 1 Update | |
Labafenogene marselecobac (previously SYNB1934) Details Phenylketonuria | Failed Discontinued | |
SYNB1891 Details Solid tumor/s, Cancer | Failed Discontinued |